Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

compulsory licence

- PMLiVE

Glioblastomas – a personalised future?

Despite some recent advances treatment remains palliative

- PMLiVE

Lilly thrown a lifeline on US Alimta patent

Court backs protection from generics until 2022

- PMLiVE

GSK halts bid for Votrient maintenance use

Pulls European application for indication in advanced ovarian cancer

- PMLiVE

Final NICE backing for MabThera in rare condition

Roche drug available in England and Wales to treat rare form of vasculitis

National Institute for Health and Care Excellence NICE logo

Boehringer cancer drug on course for NHS use in UK

NICE backs Giotrif in draft guidance

- PMLiVE

FDA approves new indication for Pfizer/BMS’ Eliquis

Oral anticoagulant gains US approval for deep vein thrombosis use

- PMLiVE

Pharma’s winners and losers in 2013

Roche, Johnson & Johnson and Amgen rise up the PMLiVE Top Pharma List rankings

- PMLiVE

Pfizer still number one – just

The PMLiVE Top Pharma List is updated with a ranking of the 25 biggest companies in the industry

- PMLiVE

GSK raises stake in Indian subsidiary

Company eyes long-term growth of market

- PMLiVE

Roche appoints new oncology research head

William Pao leaves academia for pharma role

- PMLiVE

New data puts Jakafi on course for blockbuster status

Novartis/Incyte drug meets targets in blood cancer trial

- PMLiVE

Generic for Lilly’s Evista in US ‘within a month’

Teva to launch copy of osteoporosis drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links